Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.37201/req/028.2020 http://scihub22266oqcxt.onion/10.37201/req/028.2020 32239125!7262386!32239125     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Esp+Quimioter 2020 ; 33 (3): 176-179 Nephropedia Template TP {{tp|p=32239125|t=2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 |pdf=|usr=}}{{32239125}} gab.com Text Remdesivir, la esperanza antiviral frente al SARS-CoV-2 JO: Rev Esp Quimioter http://www.kidney.de/pget.php?&tw=1&pmid=32239125 #FOAvip On December 31, 2019 a pneumonia outbreak caused by a new coronavirus (SARS-CoV-2) was detected in the city of Wuhan (China). Due to the high capacity of diffusion and human infection it has become a new zoonotic pandemic. The absence of a vaccine has determined the search for antiviral drugs with the capacity to inhibit the replication of the new virus. Among them, remdesivir, an analogue of adenosine, is what seems to have a more promising future. This drug has shown in vitro and in animals a high capacity to block infection and viral replication with attainable concentrations in human plasma. Although all studies have been carried out with SARS-CoV and MERS-CoV, it seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy. However, studies and clinical trials in humans are required to know the result of their application in them. Twit Text FOAVip Remdesivir, la esperanza antiviral frente al SARS-CoV-2 ????Rev Esp Quimioter http://www.kidney.de/pget.php?&tw=1&pmid=32239125 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32239125 #FOAvip English Wikipedia <ref>{{Cite pmid|32239125}}</ref> Remdesivir, la esperanza antiviral frente al SARS-CoV-2 #MMPMID32239125 Reina J Rev Esp Quimioter 2020[Jun]; 33 (3): 176-179 PMID32239125show ga On December 31, 2019 a pneumonia outbreak caused by a new coronavirus (SARS-CoV-2) was detected in the city of Wuhan (China). Due to the high capacity of diffusion and human infection it has become a new zoonotic pandemic. The absence of a vaccine has determined the search for antiviral drugs with the capacity to inhibit the replication of the new virus. Among them, remdesivir, an analogue of adenosine, is what seems to have a more promising future. This drug has shown in vitro and in animals a high capacity to block infection and viral replication with attainable concentrations in human plasma. Although all studies have been carried out with SARS-CoV and MERS-CoV, it seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy. However, studies and clinical trials in humans are required to know the result of their application in them. |*Betacoronavirus[MESH] |Adenosine Monophosphate/*analogs & derivatives/chemistry/therapeutic use[MESH] |Alanine/*analogs & derivatives/chemistry/therapeutic use[MESH] |Antiviral Agents/chemistry/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology[MESH]Remdesivir, la esperanza antiviral frente al SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing